Key facts
- This page summarizes Temasek Holdings (Private) Ltd's Form 3 filing for Pear Therapeutics, Inc..
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 09 Dec 2021, 20:08.
Temasek Holdings (Private) Ltd - 03 Dec 2021 Form 3 Insider Report for Pear Therapeutics, Inc.
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 03 Dec 2021
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 09 Dec 2021, 20:08:17 UTC
- Prior SEC filing
- 30 Aug 2021
- Next SEC filing
- 14 Feb 2022
- Source filing
- View source filing
- Reporting owner signature
- TLS Beta Pte. Ltd., By: /s/ Fidah Alsagoff, Authorised Signatory
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Temasek Holdings (Private) Ltd filed Form 3 for Pear Therapeutics, Inc. on 09 Dec 2021.
Change
- Previous filing in this sequence was filed on 30 Aug 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PEARQ
holding
Class A Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 26,803,573
- Date
- 03 Dec 2021
- Ownership
- See footnotes
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The securities reported herein consist of 24,903,573 shares of Class A Common Stock of Pear Therapeutics, Inc. (the "Company") directly held by TLS Beta Pte. Ltd and 1,900,000 shares of Class A Common Stock of the Company directly held by Elbrus Investments Pte. Ltd.
Footnote F2
Each of TLS Beta Pte. Ltd. and Elbrus Investments Pte. Ltd. is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited ("TLS"). TLS is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. TLS, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by each of TLS Beta Pte. Ltd. and Elbrus Investments Pte. Ltd. Each Reporting Owner disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.